Thromboxane B₂ ELISA Kit

Thromboxane A₂ (TXA₂) is produced from arachidonic acid by many cells and causes irreversible platelet aggregation and contraction of vascular and bronchial smooth muscle.^1,2,3 Like most lipid mediators, TXA₂ is not a circulating hormone. It is formed in response to local stimuli and exerts its effects within a short distance of its biosynthesis. TXA₂ is rapidly hydrolyzed non-enzymatically to form TXB₂, which is then quickly metabolized (t_½ = 5-7 minutes) to urinary metabolites for clearance by the kidneys.⁴ Because of the transient nature of this compound it is difficult to accurately measure circulating levels in whole animal experimental models. In fact, it has been shown that plasma and urine levels of TXB₂ are primarily due to ex vivo platelet activation and intra-renal production, respectively.^4,5,6 Therefore, measurement of TXB₂ metabolites, such as 11-dehydro TXB₂ (Item No. 519510), in urine and plasma may give more accurate estimates of in vivo TXA₂ production.^7,8,9 TXB₂ measurement is better suited for samples that are unlikely to undergo extensive metabolism such as perfusates, lavage samples, tissue/cell culture, etc.

Needed but not supplied: Please download the kit booklet to verify if UltraPure Water (Milli-Q or equivalent) or any other components are needed for this assay.

WARNING This product is not for human or veterinary use.

1. Hamberg, M., Svensson, J., and Samuelsson, B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA 72(8), 2994-2998 (1975).

2. Ellis, E.F., Oelz, O., Roberts, L.J., II, et al. Coronary arterial smooth muscle contraction by a substance released from platelets: Evidence that it is thromboxane A₂. Science 193(4258), 1135-1137 (1976).

3. Salzman, P.M., Salmon, J.A., and Moncada, S. Prostacyclin and thromboxane A₂ synthesis by rabbit pulmonary artery. J. Pharmacol. Exp. Ther. 215(1), 240-247 (1980).

4. Patrono, C., Ciabattoni, G., Pugliese, F., et al. Estimated rate of thromboxane secretion into the circulation of normal humans. J. Clin. Invest. 77(2), 590-594 (1986).

5. Patrono, C., Ciabattoni, G., Patrignani, P., et al. Evidence for a renal origin of urinary thromboxane B₂ in health and disease. Adv. Prostaglandin Thromboxane Leukot. Res. 11, 493-498 (1983).

6. Samuelsson, B., Granström, E., Green, K., et al. Prostaglandins. Annu. Rev. Biochem. 44, 669-695 (1975).

7. Catella, F., Healy, D., Lawson, J.A., et al. 11-dehydro Thromboxane B₂: A quantitative index of thromboxane A₂ formation in the human circulation. Proc. Natl. Acad. Sci. USA 83(16), 5861-5865 (1986).

8. Ciabattoni, G., Pugliese, F., Davi, G., et al. Fractional conversion of thromboxane B₂ to urinary 11-dehydrothromboxane B₂ in man. Biochim. Biophys. Acta 992(1), 66-70 (1989).

9. Murphy, R.C., and Fitzgerald, G.A. Current approaches to estimation of eicosanoid formation in vivo. Adv. Prostaglandin Thromboxane Leukot. Res. 22, 341-348 (1994).

Yang, J., Yamashita-Kanemaru, Y., Morris, B.I., et al. Aspirin prevents metastasis by limiting platelet TXA₂ suppression of T cell immunity. Nature (2025).

Nam, G.S., Kim, S., Kwon, Y.-S., et al. A new function for MAP4K4 inhibitors during platelet aggregation and platelet-mediated clot retraction. Biochem. Pharmacol. 188, 114519 (2021).

Liu, G., Yuan, Z., Tian, X., et al. Pimpinellin inhibits collagen-induced platelet aggregation and activation through inhibiting granule secretion and PI3K/Akt pathway. Front. Pharmacol. 12, 706363 (2021).

Ren, R.F., Hashimoto, T., Mizuno, M., et al. A lipid peroxidation product 9-oxononanoic acid induces phospholipase A₂ activity and thromboxane A₂ production in human blood. J. Clin. Biochem. Nutr. 52(3), 228-233 (2013).

Chávez-Piña, A.E., McKnight, W., Dicay, M., et al. Mechanisms underlying the anti-inflammatory activity and gastric safety of acemetacin. Br. J. Pharmacol. 152(6), 930-938 (2007).

McCann, M.E., Rickes, E.L., Hora, D.F., et al. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia. Am. J. Vet. Res. 66(7), 1278-1284 (2005).

McCann, M.E., Andersen, D.R., Zhang, D., et al. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. Am. J. Vet. Res. 65(4), 503-512 (2004).

Feng, N.K.O., Chang, Y.L., Kuo, Y.H., et al. Daphnoretin, a new protein kinase C activator isolated from Wikstroemia indica C.A. Mey. Biochem J. 295(Pt 1), 321-327 (1993).